ArticleStem cells international2012
Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap.
Article in Stem cells international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges.Annals of translational medicine · 2024Review
- Mechanotransduction of mesenchymal stem cells (MSCs) during cardiomyocytes differentiation.Heliyon · 2022Review
- Functions of Mesenchymal Stem Cells in Cardiac Repair.Advances in experimental medicine and biology · 2021Article
- Mechanotransduction of vocal fold fibroblasts and mesenchymal stromal cells in the context of the vocal fold mechanome.Journal of biomechanics · 2019Article
- Cardiomyogenic Heterogeneity of Clonal Subpopulations of Human Bone Marrow Mesenchymal Stem Cells.Journal of stem cells & regenerative medicine · 2018Article
- Article
- Article
- Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells.Molecular imaging and biology · 2016Article
- Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Review
- Cell-cell interaction between vocal fold fibroblasts and bone marrow mesenchymal stromal cells in three-dimensional hyaluronan hydrogel.Journal of tissue engineering and regenerative medicine · 2016Article
- A novel method for differentiation of human mesenchymal stem cells into smooth muscle-like cells on clinically deliverable thermally induced phase separation microspheres.Tissue engineering. Part C, Methods · 2015Article
- From bench to bedside: use of human adipose-derived stem cells.Stem cells and cloning : advances and applications · 2015Review
- Renin inhibition improves the survival of mesenchymal stromal cells in a mouse model of myocardial infarction.Journal of cardiovascular translational research · 2014Article
- Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy.Molecular and cellular biochemistry · 2014Article
- Stem cell therapy for chronic heart failure: an updated appraisal.Expert opinion on biological therapy · 2013Review
- Comparison of the direct effects of human adipose- and bone-marrow-derived stem cells on postischemic cardiomyoblasts in an in vitro simulated ischemia-reperfusion model.Stem cells international · 2013Article
- Key developments in stem cell therapy in cardiology.Regenerative medicine · 2012Review
- NF-E2-related factor 2 over-expression in mesenchymal stem cells to improve cellular cardiomyoplasty.Electronic physicianArticle
- Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the incredible boost in stem cell research has kindled the expectations of both patients and physicians. Mesenchymal progenitors, owing to their availability, ease of manipulation, and therapeutic potential, have become one of the most attractive options for the treatment of a wide range of diseases, from cartilage defects to cardiac disorders. Moreover, their immunomodulatory capacity has opened up their allogenic use, consequently broadening the possibilities for their application. In this review, we will focus on their use in the therapy of myocardial infarction, looking at their characteristics, in vitro and in vivo mechanisms of action, as well as clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.